COMPASS Pathways plc (NASDAQ:CMPS) Shares Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC grew its stake in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 205.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 126,636 shares of the company's stock after buying an additional 85,213 shares during the quarter. Cubist Systematic Strategies LLC owned 0.19% of COMPASS Pathways worth $479,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways in the 4th quarter worth about $41,000. Flagship Harbor Advisors LLC acquired a new position in COMPASS Pathways in the 4th quarter worth about $43,000. Wealthfront Advisers LLC acquired a new position in COMPASS Pathways in the 4th quarter worth about $43,000. Conservest Capital Advisors Inc. raised its holdings in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after purchasing an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. acquired a new position in COMPASS Pathways in the 4th quarter worth about $54,000. Institutional investors and hedge funds own 46.19% of the company's stock.

Analyst Ratings Changes

CMPS has been the subject of a number of analyst reports. Cantor Fitzgerald raised COMPASS Pathways to a "strong-buy" rating in a report on Tuesday, May 13th. Canaccord Genuity Group cut their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday, May 12th. Finally, Stifel Nicolaus initiated coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, COMPASS Pathways has a consensus rating of "Buy" and a consensus price target of $20.20.

COMPASS Pathways Price Performance

NASDAQ:CMPS traded down $0.16 during trading hours on Thursday, hitting $4.19. 150,191 shares of the stock were exchanged, compared to its average volume of 827,044. COMPASS Pathways plc has a 52-week low of $2.49 and a 52-week high of $8.54. The firm's fifty day moving average price is $3.41 and its 200 day moving average price is $3.94. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a market cap of $388.57 million, a P/E ratio of -1.90 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. As a group, equities research analysts anticipate that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.